Recent Quotes (30 days)

You have no recent quotes
chg | %

biOasis Technologies Inc  

(Public, CVE:BTI)   Watch this stock  
Find more results for BTI
+0.020 (2.15%)
Oct 16 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.88 - 0.96
52 week 0.61 - 1.67
Open 0.93
Vol / Avg. 80,966.00/56,856.00
Mkt cap 48.91M
P/E     -
Div/yield     -
EPS -0.06
Shares 51.57M
Beta 1.23
Inst. own     -

Key stats and ratios

Q2 (May '17) 2017
Net profit margin -240.60% -583.03%
Operating margin -239.33% -582.06%
EBITD margin - -572.22%
Return on average assets -78.67% -183.27%
Return on average equity -101.51% -287.21%
CDP Score - -


130-10691 Shellbridge Way
+1-604-2957014 (Phone)
+1-604-2788785 (Fax)

Website links


biOasis Technologies Inc. is a development-stage biopharmaceutical company, which is focused on research, development and commercialization of technologies and products that are intended for the treatment of central nervous system (CNS) diseases and diseases of the brain. The Company researches and develops products for diagnosis and treatment of neurological diseases and disorders. It is engaged in the development of its vectors Transcend and Transcendpep for the transport of therapeutic agents across the blood brain barrier (BBB). The Transcend brain delivery platform exploits the BBB penetrating properties of a recombinant soluble human protein known as melanotransferrin (MTf or p97) and portions thereof. Transcend delivery molecules have the ability to transport a range of molecules across the BBB. The Company owns approximately 30 the United States and foreign patents/applications related to p97 as a BBB delivery vector and as a biomarker for Alzheimer's disease.

Officers and directors

Robin B. Hutchison Executive Chairman of the Board
Age: 59
Mark Day Ph.D. President, Chief Executive Officer, Director
Christopher P. Lowe Chief Financial Officer
Age: 47
Doug Williams Executive Vice-President, Chief Business Officer
Mahalakshmi Radhakrishnan M.D. Director
Deborah Ann Rathjen Ph.D. Director
Nancy E. Stagliano Ph.D. Director
Ronald P. Erickson Independent Director
Age: 72